Lead Product(s) : Ixabepilone,Capecitabine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : R-Pharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Vector Pharma FZCO signs Exclusive License and Distribution Rights to IXEMPRA in the Middle East
Details : Under the agreement, R-PHARM US has appointed Vector Pharma as exclusive distributor to import, use, market, sell and distribute Ixempra (ixabepilone) in the Middle East & North African territories.
Product Name : Ixempra
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 22, 2021
Lead Product(s) : Ixabepilone,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : R-Pharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Details : Ixabepilone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2021
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Allarity is currently conducting a DRP®-guided Phase 2 clinical trial to evaluate IXEMPRA® for the treatment of third-line metastatic breast cancer, with numerous trial sites planned in Europe, including Belgium, England, Denmark, Finland, Poland and G...
Product Name : Ixempra
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 04, 2021
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Negma Group
Deal Size : $1.1 million
Deal Type : Agreement
Details : This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, steno...
Product Name : Ixempra
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 11, 2021
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Negma Group
Deal Size : $1.1 million
Deal Type : Agreement
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Negma Group
Deal Size : $1.2 million
Deal Type : Financing
Details : This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, steno...
Product Name : Ixempra
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 22, 2020
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Negma Group
Deal Size : $1.2 million
Deal Type : Financing
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Negma Group
Deal Size : $11.7 million
Deal Type : Financing
Details : This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, steno...
Product Name : Ixempra
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 05, 2020
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Negma Group
Deal Size : $11.7 million
Deal Type : Financing
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : R-Pharm US
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Details : Ixabepilone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Ovarian Epithelial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 28, 2017
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : R-Pharm US
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Susan G. Komen for the Cure | Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ixabepilone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 06, 2011
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Susan G. Komen for the Cure | Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Ixabepilone + Carboplatin Metastatic Breast Cancer
Details : Ixabepilone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 24, 2010
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Genentech | Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Details : Ixabepilone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2010
Lead Product(s) : Ixabepilone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Genentech | Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
